Literature DB >> 12833174

Potential role of transforming growth factor beta1 in drug resistance of tumor cells.

Rostyslav Stoika1, Mariya Yakymovych, Serhiy Souchelnytskyi, Ihor Yakymovych.   

Abstract

Acquired drug resistance of tumor cells is frequently observed in cancer patients undergoing chemotherapy. We studied murine leukemia L1210 cells sensitive and resistant to the cytotoxic action of cisplatin and showed that cisplatin-resistant leukemia cells were also refractory to TGF beta1-dependent growth inhibition and apoptosis. Addressing the question about the mechanisms responsible for the cross-resistance to cisplatin and TGF beta1, we found that cisplatin- and TGF beta1-resistant L1210 cells possessed a decreased expression of type I TGF beta1 receptor, while the expression of type II TGF beta1 receptor was not affected. Western blot analysis of Smad proteins 2, 3, 4, 6, and 7, which participate in signal transduction pathway down-stream of the TGF beta1 receptors, revealed an increased expression of Smad 6, inhibiting TGF beta1 action, only in cisplatin- and TGF beta1-resistant L1210 cells. TGF beta1 and especially the cytotoxic mistletoe agglutinin increased Smad 6 expression in TGF beta1-sensitive but not in TGF beta1-resistant L1210 cells. TGF beta1-resistant L1210 cells also differed from TGF beta1-sensitive cells by the lack of expression of the pro-apoptotic p53 protein and higher level of expression of the anti-apoptotic Bcl-2 protein. Thus, the described co-expression of tumor cell refractoriness to an anti-cancer drug and to the inhibitory cytokine TGF beta1 is accompanied by multiple changes in the TGF beta1 signal transduction pathway and in other regulatory systems of the target cells. Besides, we found that various anti-tumor drugs and cytotoxic plant lectins increased the level of TGF beta1 expression in both TGFbeta1-sensitive and -resistant L1210 cells. A hypothesis is proposed that TGFbeta1 can at least partly mediate the effect of cell-stressing agents and, thus, the development of TGF beta1 resistance may be responsible for the appearance of tumor cell refractoriness to the action of some anti-cancer drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12833174     DOI: 035002497

Source DB:  PubMed          Journal:  Acta Biochim Pol        ISSN: 0001-527X            Impact factor:   2.149


  6 in total

1.  Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer.

Authors:  Moubin Lin; David J Stewart; Margaret R Spitz; Michelle A T Hildebrandt; Charles Lu; Jie Lin; Jian Gu; Maosheng Huang; Scott M Lippman; Xifeng Wu
Journal:  Carcinogenesis       Date:  2011-04-22       Impact factor: 4.944

2.  The predictive value of genes of the TGF-beta1 pathway in multimodally treated squamous cell carcinoma of the esophagus.

Authors:  Franziska Pühringer-Oppermann; Mario Sarbia; Nicola Ott; Björn L D M Brücher
Journal:  Int J Colorectal Dis       Date:  2009-12-15       Impact factor: 2.571

3.  Long-term smoking mediated down-regulation of Smad3 induces resistance to carboplatin in non-small cell lung cancer.

Authors:  Debangshu Samanta; Jacob Kaufman; David P Carbone; Pran K Datta
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

4.  Neoadjuvant therapy affects tumor growth markers in early stage non-small-cell lung cancer.

Authors:  J Chorostowska-Wynimko; J Zaleska; M Chabowski; A Szpechcinski; J Zych; P Rudzinski; R Langfort; T Orlowski; K Roszkowski-Sliz
Journal:  Eur J Med Res       Date:  2009-12-07       Impact factor: 2.175

5.  MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines.

Authors:  Smriti Kumar; Arooshi Kumar; Parag P Shah; Shesh N Rai; Siva K Panguluri; Sham S Kakar
Journal:  J Ovarian Res       Date:  2011-09-22       Impact factor: 4.234

6.  TGFbeta1 signaling via alphaVbeta6 integrin.

Authors:  Martin P Kracklauer; Christian Schmidt; Guido M Sclabas
Journal:  Mol Cancer       Date:  2003-08-07       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.